Perelman School of Medicine at the University of Pennsylvania

Penn Institute for Immunology

Michael C. Milone

faculty photo
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
3400 Spruce Street 7103 Founders Pavilion
Philadelphia, PA 19104
Office: 215-662-6575
Fax: 215-662-7529
Education:
B.S (Chemical Biology)
Stevens Institute of Technology, 1993.
Ph.D (Experimental Pathology/ Immunology)
UMDNJ - Graduate School of Biomedical Sciences, 1999.
M.D. (Medical Doctor)
UMDNJ- New Jersey Medical School, 1999.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease. Active research projects in my laboratory include:

1) Developing chimeric antigen receptors (CARs) for adoptive immunotherapy of cancer with enhanced function and improved safety.

2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.

3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.

Description of Clinical Expertise

Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis

Selected Publications

O'Connor Roddy S, Guo Lili, Ghassemi Saba, Snyder Nathaniel W, Worth Andrew J, Weng Liwei, Kam Yoonseok, Philipson Benjamin, Trefely Sophie, Nunez-Cruz Selene, Blair Ian A, June Carl H, Milone Michael C: The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Scientific reports 8(1): 6289, Apr 2018.

Richman Sarah A, Milone Michael C: Neurotoxicity Associated with a High-Affinity GD2 CAR-Response. Cancer immunology research 6(4): 496-497, Apr 2018.

Laetsch Theodore W, Maude Shannon L, Milone Michael C, Davis Kara L, Krueger Joerg, Cardenas Ana Maria, Eldjerou Lamis K, Keir Christopher H, Wood Patricia A, Grupp Stephan A: False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods. Blood Apr 2018.

Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 3(8), Apr 2018.

Milone Michael C, O'Doherty Una: Clinical use of lentiviral vectors. Leukemia Mar 2018.

Michael C. Milone and Bruce L. Levine: Powered and controlled T-cell production. Nature Biomedical Engineering 2: 148-150, 2018.

De-xiu Bu, Reshma Singh, Eugene E. Choi,*, Marco Ruella, Selene Nunez- Cruz, Keith G. Mansfi eld, Paul Bennett, Nathanial Barton, Qilong Wu, Jiquan Zhang, Yongqiang Wang, Lai Wei, Shawn Cogan, Tucker Ezell, Shree Joshi, Kellie J. Latimer, Brian Granda, William R. Tschantz, Regina M. Young, Heather A. Huet, Celeste J. Richardson and Michael C. Milone: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget In Press, 2018.

June Carl H, O'Connor Roderick S, Kawalekar Omkar U, Ghassemi Saba and Milone Michael C: CAR T cell immunotherapy for human cancer. Science 359(6382): 1361-1365, 2018.

Vijay Bhoj and Michael C. Milone: The pharmacology of T cell therapies. Molecular Therapy - Methods & Clinical Development 8: 210-221, 2018.

Trofe-Clark Jennifer, Brennan Daniel C, West-Thielke Patricia, Milone Michael C, Lim Mary Ann, Neubauer Robin, Nigro Vincenza, Bloom Roy D: Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. American journal of kidney diseases : the official journal of the National Kidney Foundation Nov 2017.

back to top
Last updated: 05/18/2018
The Trustees of the University of Pennsylvania